Base de dados : MEDLINE
Pesquisa : D03.066.288.200 [Categoria DeCS]
Referências encontradas : 447 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 45 ir para página                         

  1 / 447 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28641674
[Au] Autor:Vergili I; Gencdal S
[Ti] Título:Removal of Organic Matter and Etodolac from Pharmaceutical Industry Wastewater by PAC Adsorption.
[So] Source:Water Environ Res;89(7):641-651, 2017 Jul 01.
[Is] ISSN:1061-4303
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The removal of organic matter and etodolac (an anti-inflammatory pharmaceutical) from a real process wastewater by using powdered activated carbon (PAC) adsorption before and after Fenton oxidation has been studied. The wastewater sample is collected from the final stage of chemical synthesis of a pharmaceutical (etodolac). Fenton oxidation resulted with decrease in chemical oxygen demand (84% removal) and etodolac concentration was reduced to 0.7 mg L-1. Optimum adsorption equilibrium conditions were found as t = 16 hours, and m = 10 g L-1. The Freundlich model showed the best fit for the adsorption of both wastewater with R2 values of 0.89 and 0.99. Lower pseudo-second-order rate constant (k2) (0.067 < 2.62) obtained from the adsorption of raw wastewater with higher organic matter concentration confirms the chemisorption of the adsorbates onto the PAC. Pore surface mass diffusion with R2 value of 0.92 was found as rate-controlling step for adsorption process with Fenton pre-treated wastewater.
[Mh] Termos MeSH primário: Carvão Vegetal/química
Etodolac/química
Resíduos Industriais
Eliminação de Resíduos Líquidos/métodos
Águas Residuais/química
Poluentes Químicos da Água/química
[Mh] Termos MeSH secundário: Adsorção
Inibidores de Ciclo-Oxigenase 2/química
Indústria Farmacêutica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cyclooxygenase 2 Inhibitors); 0 (Industrial Waste); 0 (Waste Water); 0 (Water Pollutants, Chemical); 16291-96-6 (Charcoal); 2M36281008 (Etodolac)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170624
[St] Status:MEDLINE
[do] DOI:10.2175/106143017X14902968254520


  2 / 447 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28388726
[Au] Autor:Janzen C; Sen S; Lei MY; Gagliardi de Assumpcao M; Challis J; Chaudhuri G
[Ad] Endereço:Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California 90095, Los Angeles, Los Angeles, California.
[Ti] Título:The Role of Epithelial to Mesenchymal Transition in Human Amniotic Membrane Rupture.
[So] Source:J Clin Endocrinol Metab;102(4):1261-1269, 2017 Apr 01.
[Is] ISSN:1945-7197
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Context: Biochemical weakening of the amnion is a major factor preceding preterm premature rupture of membranes (PPROMs), leading to preterm birth. Activation of matrix metalloproteinases (MMPs) is known to play a key role in collagen degradation of the amnion; however, epithelial to mesenchymal transition (EMT) that is also induced by MMP activation has not been investigated as a mechanism for amnion weakening. Objective: To measure amniotic EMT associated with vaginal delivery (VD) compared with unlabored cesarean sections (CSs), and to assess changes in amniotic mechanical strength with pharmacologic inhibitors and inducers of EMT, thus testing the hypothesis that EMT is a key biochemical event that promotes amniotic rupture. Findings: (1) Amnions taken from VD contained a significantly increased number of mesenchymal cells relative to epithelial cells compared with unlabored CS by fluorescence-activated cell sorting analysis (60% vs 10%); (2) tumor necrosis factor (TNF)-α stimulation of amniotic epithelial cells increased expression of the mesenchymal marker vimentin after 2 days; (3) EMT inhibitor, etodolac, significantly increased the time and mechanical pressure required to rupture the amnion; and (4) TNF-α and another pharmacologic EMT inducer, ethacridine, decreased the time and mechanical pressure required for amnion rupture, further confirming that the mesenchymal phenotype significantly weakens the amnion. Conclusions: This work demonstrated amniotic cell EMT was associated with labor and EMT decreased the tensile strength of the amnion. These findings suggest a role for EMT in the pathophysiology of PPROM and may provide a basis for development of therapies to prevent preterm labor.
[Mh] Termos MeSH primário: Âmnio/efeitos dos fármacos
Transição Epitelial-Mesenquimal/efeitos dos fármacos
Ruptura Prematura de Membranas Fetais/metabolismo
Resistência à Tração/efeitos dos fármacos
Fator de Necrose Tumoral alfa/farmacologia
[Mh] Termos MeSH secundário: Âmnio/metabolismo
Inibidores de Ciclo-Oxigenase 2/farmacologia
Etodolac/farmacologia
Feminino
Seres Humanos
Metaloproteinases da Matriz/metabolismo
Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cyclooxygenase 2 Inhibitors); 0 (Tumor Necrosis Factor-alpha); 2M36281008 (Etodolac); EC 3.4.24.- (Matrix Metalloproteinases)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170714
[Lr] Data última revisão:
170714
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170408
[St] Status:MEDLINE
[do] DOI:10.1210/jc.2016-3150


  3 / 447 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28248111
[Au] Autor:Sherje AP; Kulkarni V; Murahari M; Nayak UY; Bhat P; Suvarna V; Dravyakar B
[Ad] Endereço:Department of Quality Assurance, SVKM's Dr. Bhanuben Nanavati College of Pharmacy , Gate No. 1, SVKM Campus, V. M. Road, Vile Parle (W), Mumbai 400 056, India.
[Ti] Título:Inclusion Complexation of Etodolac with Hydroxypropyl-beta-cyclodextrin and Auxiliary Agents: Formulation Characterization and Molecular Modeling Studies.
[So] Source:Mol Pharm;14(4):1231-1242, 2017 Apr 03.
[Is] ISSN:1543-8392
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The present investigation was aimed to prepare inclusion complexes of a therapeutically important nonsteroidal anti-inflammatory drug, etodolac (ETD) with hydroxypropyl-beta-cyclodextrin (HP-ß-CD) and to study the effect of l-arginine (l-Arg) as an auxiliary agent on the complexation efficiency of HP-ß-CD to improve aqueous solubility and the dissolution property of ETD. The binary and ternary complexes were prepared by physical mixing, coevaporation, and spray drying methods. The complexes were characterized using differential scanning colorimetry (DSC), Fourier transform-infrared spectroscopy (FT-IR), and powder X-ray diffraction (PXRD) studies. The mechanism of inclusion interaction of guest and host was established through H NMR, molecular docking, and molecular dynamics studies. On the basis of preliminary screening studies, l-Arg was found to be the most efficient auxiliary agent for the present research problem. The change in crystallinity of ETD was evident from DSC and PXRD studies which indicated the formation of new solid forms. A remarkable increase in apparent stability constant (K ) and complexation efficiency (CE) of HP-ß-CD was observed in the presence of l-Arg in ternary complexes with improvement in solubility and dissolution of ETD than binary complexes. However, inclusion complexes of ETD obtained by computational studies is in good correlation with the results obtained through experimental methods. More stable complex formation with l-Arg was confirmed by molecular simulation studies too. Thus, the present study led to the conclusion that the ternary complex of ETD-HP-ß-CD-l-Arg could be an innovative approach to augment the solubility and dissolution behavior of ETD.
[Mh] Termos MeSH primário: Arginina/química
Etodolac/química
beta-Ciclodextrinas/química
[Mh] Termos MeSH secundário: 2-Hidroxipropil-beta-Ciclodextrina
Varredura Diferencial de Calorimetria/métodos
Química Farmacêutica/métodos
Liofilização/métodos
Modelos Moleculares
Simulação de Acoplamento Molecular/métodos
Pós/química
Solubilidade
Espectroscopia de Infravermelho com Transformada de Fourier/métodos
Difração de Raios X/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Powders); 0 (beta-Cyclodextrins); 1I96OHX6EK (2-Hydroxypropyl-beta-cyclodextrin); 2M36281008 (Etodolac); 94ZLA3W45F (Arginine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE
[do] DOI:10.1021/acs.molpharmaceut.6b01115


  4 / 447 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28154306
[Au] Autor:Shiraishi S; Haraguchi T; Nakamura S; Li D; Kojima H; Yoshida M; Uchida T
[Ad] Endereço:Faculty of Pharmaceutical Science, Mukogawa Women's University.
[Ti] Título:Taste-Masking Effect of Chlorogenic Acid (CGA) on Bitter Drugs Evaluated by Taste Sensor and Surface Plasmon Resonance on the Basis of CGA-Drug Interactions.
[So] Source:Chem Pharm Bull (Tokyo);65(2):127-133, 2017.
[Is] ISSN:1347-5223
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:The purpose of this study was to evaluate the taste-masking effects of chlorogenic acid (CGA) on bitter drugs using taste sensor measurements and surface plasmon resonance (SPR) analysis of CGA-drug interactions. Six different bitter drugs were used: amlodipine besylate (AMD), diphenhydramine hydrochloride (DPH), donepezil hydrochloride (DNP), rebamipide (RBM), diclofenac sodium (DCF) and etodolac (ETD). Taste sensor outputs were significantly inhibited by the addition of CGA to all drugs. The inhibition ratio of the taste sensor output decreased in the following order DPH>DNP>AMD≈DCF≈RBM≈ETD. The association rate constant (k ) for the interaction between drugs and CGA as evaluated by SPR measurement also decreased in the following order DPH>DNP>AMD>DCF≈ETD≈RBM. It was suggested that basic drugs (AMD, DNP, DPH) associate more easily with CGA than acidic drugs (DCF, RBM, ETD). The inhibition ratios (%) of the taste sensor output of bitter drugs caused by CGA and the association rate constants (k ) between the drugs and CGA were significantly correlated (r =0.886, p<0.05, Spearman's correlation test). Our findings suggest that the taste-masking effects of CGA are due to its direct association with the drugs. CGA may therefore be a useful taste-masking agent for basic drugs.
[Mh] Termos MeSH primário: Ácido Clorogênico/farmacologia
Interações Medicamentosas
Ressonância de Plasmônio de Superfície
Paladar/efeitos dos fármacos
[Mh] Termos MeSH secundário: Alanina/análogos & derivados
Anlodipino/farmacologia
Diclofenaco/farmacologia
Difenidramina/farmacologia
Etodolac/farmacologia
Indanos/farmacologia
Piperidinas/farmacologia
Quinolonas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Indans); 0 (Piperidines); 0 (Quinolones); 144O8QL0L1 (Diclofenac); 1J444QC288 (Amlodipine); 2M36281008 (Etodolac); 318ADP12RI (Chlorogenic Acid); 8GTS82S83M (Diphenhydramine); 8SSC91326P (donepezil); LR583V32ZR (rebamipide); OF5P57N2ZX (Alanine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170314
[Lr] Data última revisão:
170314
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170204
[St] Status:MEDLINE
[do] DOI:10.1248/cpb.c16-00621


  5 / 447 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27160363
[Au] Autor:Silva de Oliveira JC; Grossi de Oliveira GA; Bassi AP
[Ad] Endereço:Resident, Maxillofacial Surgery Program, Araraquara Dental School, Universidade Estadual Paulista-UNESP, Araraquara, Brazil.
[Ti] Título:Comparative Assessment of the Effect of Ibuprofen and Etodolac on Edema, Trismus, and Pain in Lower Third Molar Surgery: A Randomized Clinical Trial.
[So] Source:J Oral Maxillofac Surg;74(8):1524-30, 2016 Aug.
[Is] ISSN:1531-5053
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To compare the efficacy of ibuprofen (IBU) and etodolac (ETO) for controlling pain, edema, and trismus after extraction of lower third molars. MATERIALS AND METHODS: Twenty adolescents and adults with 2 impacted mandibular-third molars (in similar positions) were selected for the study. Patients were randomly assigned either to the IBU group (600 mg of IBU 3 times a day for 3 days) or to the ETO group (300 mg of ETO 3 times a day for 3 days). Drugs were administered immediately after dental extraction. RESULTS: During the first 2 days after extraction, swelling was more pronounced in the IBU group than in the ETO group (P = .033). Seven days after surgery, there was no difference in the degree of edema between the groups. At the 2- and 7-day evaluation points, mouth opening was significantly more reduced in the IBU group than in the ETO group (P < .05). After the first 6 hours, the ETO group had more effective pain relief (P < .05), but after this time point, both groups reported similar degrees of relief. Compared with the IBU group, the ETO group had a lower need for administration of additional rescue analgesics. CONCLUSIONS: After extraction of impacted lower third molars, we found that swelling, trismus, and pain were more effectively controlled with ETO than with IBU.
[Mh] Termos MeSH primário: Inibidores de Ciclo-Oxigenase 2/uso terapêutico
Edema/tratamento farmacológico
Etodolac/uso terapêutico
Ibuprofeno/uso terapêutico
Dente Serotino/cirurgia
Dor Pós-Operatória/tratamento farmacológico
Dente Impactado/cirurgia
Trismo/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Feminino
Seres Humanos
Masculino
Mandíbula/cirurgia
Manejo da Dor
Medição da Dor
Extração Dentária
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Cyclooxygenase 2 Inhibitors); 2M36281008 (Etodolac); WK2XYI10QM (Ibuprofen)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:AIM; D; IM
[Da] Data de entrada para processamento:160511
[St] Status:MEDLINE


  6 / 447 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27105592
[Au] Autor:Singh M; Bhushan R
[Ad] Endereço:Department of Chemistry, Indian Institute of Technology Roorkee, Roorkee, 247667, India.
[Ti] Título:HPLC enantioseparation of racemic bupropion, baclofen and etodolac: modification of conventional ligand exchange approach by pre-column formation of chiral ligand exchange complexes.
[So] Source:Biomed Chromatogr;30(11):1728-1732, 2016 Nov.
[Is] ISSN:1099-0801
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Separation of racemic mixture of (RS)-bupropion, (RS)-baclofen and (RS)-etodolac, commonly marketed racemic drugs, has been achieved by modifying the conventional ligand exchange approach. The Cu(II) complexes were first prepared with a few l-amino acids, namely, l-proline, l-histidine, l-phenylalanine and l-tryptophan, and to these was introduced a mixture of the enantiomer pair of (RS)-bupropion, or (RS)-baclofen or (RS)-etodolac. As a result, formation of a pair of diastereomeric complexes occurred by 'chiral ligand exchange' via the competition between the chelating l-amino acid and each of the two enantiomers from a given pair. The diastereomeric mixture formed in the pre-column process was loaded onto HPLC column. Thus, both the phases during chromatographic separation process were achiral (i.e. neither the stationary phase had any chiral structural feature of its own nor did the mobile phase have any chiral additive). Separation of diastereomers was successful using a C column and a binary mixture of MeCN and TEAP buffer of pH 4.0 (60:40, v/v) as mobile phase at a flow rate of 1 mL/min and UV detection at 230 nm for (RS)-Bup, 220 nm for (RS)-Bac and 223 nm for (RS)-Etd. Baseline separation of the two enantiomers was obtained with a resolution of 6.63 in <15 min. Copyright © 2016 John Wiley & Sons, Ltd.
[Mh] Termos MeSH primário: Antidepressivos de Segunda Geração/isolamento & purificação
Baclofeno/isolamento & purificação
Bupropiona/isolamento & purificação
Cromatografia Líquida de Alta Pressão/métodos
Inibidores de Ciclo-Oxigenase 2/isolamento & purificação
Etodolac/isolamento & purificação
Relaxantes Musculares Centrais/isolamento & purificação
[Mh] Termos MeSH secundário: Aminoácidos/química
Antidepressivos de Segunda Geração/química
Baclofeno/química
Bupropiona/química
Complexos de Coordenação/química
Cobre/química
Inibidores de Ciclo-Oxigenase 2/química
Etodolac/química
Ligantes
Relaxantes Musculares Centrais/química
Estereoisomerismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amino Acids); 0 (Antidepressive Agents, Second-Generation); 0 (Coordination Complexes); 0 (Cyclooxygenase 2 Inhibitors); 0 (Ligands); 0 (Muscle Relaxants, Central); 01ZG3TPX31 (Bupropion); 2M36281008 (Etodolac); 789U1901C5 (Copper); H789N3FKE8 (Baclofen)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170124
[Lr] Data última revisão:
170124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160424
[St] Status:MEDLINE
[do] DOI:10.1002/bmc.3746


  7 / 447 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26945484
[Au] Autor:Miwa Y; Hamamoto H; Ishida T
[Ad] Endereço:MEDRx Co., Ltd, 431-7 Nishiyama, Higashikagawa-city, Kagawa 769-2712, Japan.
[Ti] Título:Lidocaine self-sacrificially improves the skin permeation of the acidic and poorly water-soluble drug etodolac via its transformation into an ionic liquid.
[So] Source:Eur J Pharm Biopharm;102:92-100, 2016 May.
[Is] ISSN:1873-3441
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Poor transdermal penetration of active pharmaceutical ingredients (APIs) impairs both bioavailability and therapeutic benefits and is a major challenge in the development of transdermal drug delivery systems. Here, we transformed a poorly water-soluble drug, etodolac, into an ionic liquid in order to improve its hydrophobicity, hydrophilicity and skin permeability. The ionic liquid was prepared by mixing etodolac with lidocaine (1:1, mol/mol). Both the free drug and the transformed ionic liquid were characterized by differential scanning colorimetry (DSC), infrared spectroscopy (IR), and saturation concentration measurements. In addition, in vitro skin-permeation testing was carried out via an ionic liquid-containing patch (Etoreat patch). The lidocaine and etodolac in ionic liquid form led to a relatively lower melting point than either lidocaine or etodolac alone, and this improved the lipophilicity/hydrophilicity of etodolac. In vitro skin-permeation testing demonstrated that the Etoreat patch significantly increased the skin permeation of etodolac (9.3-fold) compared with an etodolac alone patch, although an Etoreat patch did not increase the skin permeation of lidocaine, which was consistent with the results when using a lidocaine alone patch. Lidocaine appeared to self-sacrificially improve the skin permeation of etodolac via its transformation into an ionic liquid. The data suggest that ionic liquids composed of approved drugs may substantially expand the formulation preparation method to meet the challenges of drugs which are characterized by poor rates of transdermal absorption.
[Mh] Termos MeSH primário: Etodolac/administração & dosagem
Etodolac/química
Líquidos Iônicos/química
Lidocaína/administração & dosagem
Lidocaína/química
Pele/metabolismo
Água/química
[Mh] Termos MeSH secundário: Administração Cutânea
Animais
Química Farmacêutica/métodos
Portadores de Fármacos/química
Feminino
Interações Hidrofóbicas e Hidrofílicas
Íons/química
Permeabilidade
Absorção Cutânea
Solubilidade
Suínos
Adesivo Transdérmico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Drug Carriers); 0 (Ionic Liquids); 0 (Ions); 059QF0KO0R (Water); 2M36281008 (Etodolac); 98PI200987 (Lidocaine)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161217
[Lr] Data última revisão:
161217
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160307
[St] Status:MEDLINE


  8 / 447 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Lanchote, Vera Lucia
Texto completo
[PMID]:26723001
[Au] Autor:de Miranda Silva C; Rocha A; Tozatto E; da Silva LM; Donadi EA; Lanchote VL
[Ad] Endereço:Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
[Ti] Título:Enantioselective analysis of etodolac in human plasma by LC-MS/MS: Application to clinical pharmacokinetics.
[So] Source:J Pharm Biomed Anal;120:120-6, 2016 Feb 20.
[Is] ISSN:1873-264X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Etodolac is a non-steroidal anti-inflammatory drug with preferential inhibition of cyclooxigenase-2 and is widely used in the management of pain in patients with inflammatory arthritis. Etodolac is available as a racemic mixture of (-)-(R)-Etodolac and (+)-(S)-Etodolac; cyclooxigenases inhibition is attributed to (+)-(S)-Etodolac. According to our knowledge, this is the first method for determination of etodolac enantiomers in plasma using LC-MS/MS. Plasma extraction were performed with 25µL of plasma and 1mL of n-hexane:ethyl acetate (95:5); racemic ibuprofen was used as internal standard. Resolution of enantiomers were performed in a Chiralcel(®)OD-H column; deprotonated [M-H](-) and their respective ion products were monitored at transitions of 286>242 for etodolac enantiomers and 205>161 for ibuprofen. The quantitation limit was 3.2ng/mL for both enantiomers in plasma. The method was applied to study the pharmacokinetics of etodolac enantiomers after the administration of a 300 and 400mg dose of racemic drug to a healthy volunteer. Analysis of plasma samples showed higher plasma concentration of (-)-(R)-Etodolacfor both doses (300mg dose: AUC(0-∞)49.80 versus 4.55ugh/mL;400mg dose: AUC(0-∞) 63.90 versus 6.00ugh/mL) with an (R)-(+)/(S)-(-) ratio of approximately 11.
[Mh] Termos MeSH primário: Etodolac/sangue
Etodolac/química
Plasma/química
[Mh] Termos MeSH secundário: Acetatos/química
Adulto
Anti-Inflamatórios não Esteroides/sangue
Anti-Inflamatórios não Esteroides/química
Cromatografia Líquida/métodos
Hexanos/química
Seres Humanos
Ibuprofeno/sangue
Ibuprofeno/química
Masculino
Estereoisomerismo
Espectrometria de Massas em Tandem/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Acetates); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Hexanes); 2DDG612ED8 (n-hexane); 2M36281008 (Etodolac); 76845O8NMZ (ethyl acetate); WK2XYI10QM (Ibuprofen)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160102
[St] Status:MEDLINE


  9 / 447 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25929857
[Au] Autor:Sariözkan S; Türk G; Çikla-Süzgün P; Güvenç M; Yüce A; Yay AH; Cantürk F; Küçükgüzel SG
[Ad] Endereço:Department of Reproduction and Artificial Insemination, Faculty of Veterinary Medicine, Erciyes University, Kayseri, Turkey.
[Ti] Título:Effect of etodolac hydrazone, a new compound synthesised from etodolac, on spermatozoon quality, testicular lipid peroxidation, apoptosis and spermatozoon DNA integrity.
[So] Source:Andrologia;48(2):177-88, 2016 Mar.
[Is] ISSN:1439-0272
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to investigate the effect of etodolac hydrazone (EH), a new compound synthesised from etodolac, on spermatozoon quality, testicular lipid peroxidation, apoptosis and spermatozoon DNA integrity in rats. Group 1 (n = 8) received 1 ml dimethyl sulfoxide (DMSO) daily (Control); group 2 (n = 8) was treated with 5 mg kg(-1)  day(-1) EH, dissolved in 1 ml DMSO (EH-5); and group 3 (n = 8) was treated with 10 mg kg(-1)  day(-1) EH, dissolved in 1 ml DMSO (EH-10). All administrations were performed by gavage and maintained for 8 weeks. Both doses of EH administration caused significant decreases in absolute and relative weights of testis, whole epididymis, right cauda epididymis, and spermatozoon motility, spermatozoon count in comparison with the control group. Only 10 mg kg(-1)  day(-1) EH administration caused significant decreases in absolute and relative weights of seminal vesicles and serum testosterone level, and significant increases in testicular lipid peroxidation level, and numbers of TUNEL+ apoptotic germ cells and spermatozoa with damaged DNA along with some histopathological damages when compared to the control group. However, body and ventral prostate weight, and testicular antioxidant markers (glutathione, glutathione-peroxidase and catalase), were unaffected significantly by both doses of EH administration. In conclusion, two different doses of EH, in particular its high dose, damage to testicular spermatogenic cells and spermatozoon DNA and, it decreases spermatozoon motility, count and testosterone level in healthy rats.
[Mh] Termos MeSH primário: Apoptose/efeitos dos fármacos
Inibidores de Ciclo-Oxigenase 2/farmacologia
Dano ao DNA/efeitos dos fármacos
Etodolac/análogos & derivados
Etodolac/farmacologia
Hidrazonas/farmacologia
Peroxidação de Lipídeos/efeitos dos fármacos
Espermatozoides/efeitos dos fármacos
Testículo/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Catalase/efeitos dos fármacos
Catalase/metabolismo
Epididimo/efeitos dos fármacos
Epididimo/patologia
Glutationa/efeitos dos fármacos
Glutationa/metabolismo
Glutationa Peroxidase/efeitos dos fármacos
Glutationa Peroxidase/metabolismo
Marcação In Situ das Extremidades Cortadas
Masculino
Tamanho do Órgão
Ratos
Glândulas Seminais/efeitos dos fármacos
Glândulas Seminais/patologia
Motilidade Espermática/efeitos dos fármacos
Testículo/metabolismo
Testosterona/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cyclooxygenase 2 Inhibitors); 0 (Hydrazones); 0 (etodolac hydrazone); 2M36281008 (Etodolac); 3XMK78S47O (Testosterone); EC 1.11.1.6 (Catalase); EC 1.11.1.9 (Glutathione Peroxidase); GAN16C9B8O (Glutathione)
[Em] Mês de entrada:1611
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150502
[St] Status:MEDLINE
[do] DOI:10.1111/and.12429


  10 / 447 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:26902001
[Au] Autor:Kanbayashi Y; Konishi H
[Ti] Título:Predictive Factors for NSAIDs-related Gastrointestinal Toxicity: Can COX-2 Selective Inhibtor Prevent it?.
[So] Source:Hepatogastroenterology;62(140):787-9, 2015 Jun.
[Is] ISSN:0172-6390
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIMS: To identify predictive factors for NSAIDs-related GI toxicity and to clarify whether cox-2 selective inhibitors can prevent it or not. METHODOLOGY: We have surveyed all patients received esophagogastroduodenoscopy examined at our hospital between January 2008 and September 2011. We performed the following retrospective analyses of the clinical records of the 253 patients prescribed NSAIDs. The severity of gastro duodenal mucosal lesions was evaluated using the modified gastro duodenal LANZA score. The following scores for response were used: 0 = no lesions (LANZA score 0); 1 = erosion and redness (LANZA score 1-3); 2 = ulcer (LANZA score 4). Predictors evaluated were factors potentially related to pathogenesis of NSAIDs related GI toxicity. Ordered logistic regression analysis was performed to identify predictive factors for NSAIDs related. ulcer. RESULTS: A multivariate logistic regression identified number of risk factors (odds ratio (OR) = 6.82, confidence interval (CI) = 5.31-8.76; P = 0.01), concomitant use of anti- cancer drugs (OR = 2.17, Cl = 1.02-4.62; P = 0.04) were found to be significant factors. CONCLUSIONS: Number of risk factors and concomitant use of anticancer drugs were shown to be predictive factors for NSAID-related GI toxicity. Use of celecoxib or proton pump inhibitor was not identified as a protective factor.
[Mh] Termos MeSH primário: Corticosteroides/uso terapêutico
Anti-Inflamatórios não Esteroides/uso terapêutico
Anticoagulantes/uso terapêutico
Antineoplásicos/uso terapêutico
Inibidores de Ciclo-Oxigenase 2/uso terapêutico
Úlcera Duodenal/epidemiologia
Inibidores da Bomba de Prótons/uso terapêutico
Úlcera Gástrica/epidemiologia
[Mh] Termos MeSH secundário: Idoso
Aspirina/uso terapêutico
Celecoxib/uso terapêutico
Estudos de Coortes
Diclofenaco/uso terapêutico
Duodenopatias/epidemiologia
Duodenopatias/patologia
Úlcera Duodenal/patologia
Endoscopia do Sistema Digestório
Etodolac/uso terapêutico
Feminino
Seres Humanos
Modelos Logísticos
Masculino
Meia-Idade
Fenilpropionatos/uso terapêutico
Fatores de Proteção
Estudos Retrospectivos
Fatores de Risco
Gastropatias/epidemiologia
Gastropatias/patologia
Úlcera Gástrica/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Anticoagulants); 0 (Antineoplastic Agents); 0 (Cyclooxygenase 2 Inhibitors); 0 (Phenylpropionates); 0 (Proton Pump Inhibitors); 144O8QL0L1 (Diclofenac); 2M36281008 (Etodolac); 3583H0GZAP (loxoprofen); JCX84Q7J1L (Celecoxib); R16CO5Y76E (Aspirin)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:160223
[Lr] Data última revisão:
160223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160224
[St] Status:MEDLINE



página 1 de 45 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde